Iovance Biotherapeutics (NASDAQ:IOVA) Stock Sees Heavy Call Option Buying

Key Points

• Heavy bullish options activity: Investors bought 28,173 IOVA call options, 70% above the average volume of 16,565 contracts.
• Shares fell sharply: Iovance stock dropped $5.25 to $9.56 amid unusually high trading volume of nearly 58.7 million shares, despite reporting quarterly revenue of $99.3 million and a narrower-than-expected loss.
• Analyst sentiment remains positive, but clinical results were mixed: The consensus rating is “Moderate Buy” with a $13.20 price target, while lung-cancer data showed a 24.6% overall response rate and stronger results in biomarker-selected groups; regulatory submission is not expected until 2027.

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Get Free Report) saw unusually large options trading activity on Thursday. Stock investors acquired 28,173 call options on the company. This is an increase of 70% compared to the average volume of 16,565 call options.

Iovance Biotherapeutics Price Performance

Shares of IOVA traded down $5.25 during midday trading on Thursday, hitting $9.56. 58,699,830 shares of the company traded hands, compared to its average volume of 15,705,564. Iovance Biotherapeutics has a one year low of $1.76 and a one year high of $15.37. The firm has a market cap of $4.33 billion, a P/E ratio of -13.10 and a beta of 0.76. The stock has a 50-day moving average of $11.35 and a 200-day moving average of $5.76.

Iovance Biotherapeutics (NASDAQ:IOVA - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The biotechnology company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.02. Iovance Biotherapeutics had a negative net margin of 89.11% and a negative return on equity of 40.51%. The company had revenue of $99.31 million during the quarter, compared to analysts' expectations of $87.83 million. During the same quarter in the previous year, the company earned ($0.33) earnings per share. Iovance Biotherapeutics's revenue for the quarter was up 65.7% on a year-over-year basis. Sell-side analysts forecast that Iovance Biotherapeutics will post -0.45 EPS for the current fiscal year.

Analyst Ratings Changes

IOVA has been the subject of a number of research analyst reports. TD Cowen raised their price objective on shares of Iovance Biotherapeutics from $7.00 to $10.00 and gave the stock a "buy" rating in a report on Monday, August 24th. Barclays raised their price target on shares of Iovance Biotherapeutics from $15.00 to $18.00 and gave the stock an "overweight" rating in a research note on Tuesday, October 13th. HC Wainwright lifted their price target on shares of Iovance Biotherapeutics from $9.00 to $20.00 and gave the stock a "buy" rating in a report on Tuesday, September 29th. Zacks Research upgraded Iovance Biotherapeutics from a "hold" rating to a "strong-buy" rating in a research note on Monday. Finally, Citigroup reissued an "outperform" rating on shares of Iovance Biotherapeutics in a report on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, Iovance Biotherapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $13.20.

Iovance Biotherapeutics News Roundup

Here are the key news stories impacting Iovance Biotherapeutics this week:

• Positive Sentiment: Iovance reported a 24.6% objective response rate among 69 patients with nonsquamous metastatic non-small-cell lung cancer in the Phase 2 IOV-LUN-202 study. The KRAS wild-type subgroup posted a 43.3% response rate, while a novel biomarker-enriched group reached 59.1%. The company said the data support a planned supplemental biologics license application for lifileucel in 2027 and will begin the POSITIVITY biomarker-enriched study in November. Iovance Reports Updated IOV-LUN-202 Results
• Positive Sentiment: Earlier melanoma-related data also showed lifileucel activity in difficult-to-treat tumors, including a reported 50% response rate in refractory undifferentiated pleomorphic sarcoma and liposarcoma, reinforcing the potential to expand Iovance’s TIL platform beyond its current melanoma use. Lifileucel Shows 50% Response Rate
• Positive Sentiment: Zacks upgraded IOVA from “hold” to “strong buy,” while unusually heavy call-option activity and expectations for an earnings beat signal continued bullish positioning among some traders. Zacks Research Rating
• Neutral Sentiment: The company’s webcast highlighted its lung-cancer results and broader precision-immuno-oncology strategy, giving investors additional details on the development pipeline. Iovance Webcast Announcement
• Negative Sentiment: The sharp selloff indicates that investors may have considered the overall 24.6% response rate less compelling than the stronger biomarker-selected results, particularly because the KRAS-mutant subgroup achieved only an 11.4% response rate. The program remains investigational, with a possible regulatory submission not expected until 2027. Iovance Lung Cancer Twist

Institutional Investors Weigh In On Iovance Biotherapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. NorthCrest Asset Manangement LLC raised its holdings in shares of Iovance Biotherapeutics by 5.4% during the 3rd quarter. NorthCrest Asset Manangement LLC now owns 13,735 shares of the biotechnology company's stock valued at $204,000 after buying an additional 707 shares in the last quarter. Arcataur Capital Management LLC raised its stake in shares of Iovance Biotherapeutics by 3.6% during the third quarter. Arcataur Capital Management LLC now owns 28,600 shares of the biotechnology company's stock worth $424,000 after acquiring an additional 1,000 shares in the last quarter. Krilogy Financial LLC lifted its holdings in shares of Iovance Biotherapeutics by 6.6% in the 3rd quarter. Krilogy Financial LLC now owns 16,662 shares of the biotechnology company's stock worth $243,000 after acquiring an additional 1,032 shares during the last quarter. Sequoia Financial Advisors LLC boosted its stake in shares of Iovance Biotherapeutics by 5.4% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 32,957 shares of the biotechnology company's stock valued at $137,000 after purchasing an additional 1,691 shares in the last quarter. Finally, Valley National Advisers Inc. purchased a new stake in shares of Iovance Biotherapeutics in the 3rd quarter valued at $38,000. Hedge funds and other institutional investors own 77.03% of the company's stock.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc NASDAQ: IOVA is a biotechnology company focused on developing and commercializing personalized cell therapies for patients with cancer. Its technology is based on tumor-infiltrating lymphocytes (TILs), immune cells collected from a patient's tumor, expanded outside the body, and reinfused to help attack cancer cells.

The company's lead product, Amtagvi (lifileucel), is an autologous TIL therapy approved in the United States for certain adults with unresectable or metastatic melanoma that has progressed following prior treatment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.